Yazar "Aksoy S." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    The decline of BCG immunity after neonatal vaccination: what about revaccination at one year?
    (1993) Aydinlioglu H.; Caglayan S.; Kansoy S.; Yaprak I.; Seckin E.; Bakiler A.R.; Aksoy S.
    Summary. Two hundred and nineteen healthy newborns were vaccinated with the BCG vaccine, and their immunity was checked thereafter at 3,6 and 12 months of age. We determined that 87% of tuberculin reactivity at 3 months declined to 61% at 12 months. Revaccination of nonreactive infants provided a 100% rate of reactivity. In the light of this information we propose a revision in the BCG vaccination programme in developing countries. We also found a close relationship between the tuberculin reactivity and scar formation after BCG vaccination, suggesting that a simple check of the left deltoid region for a BCG scar may give enough information about the child's immunity to tuberculosis. Copyright © 1993, Wiley Blackwell. All rights reserved
  • Küçük Resim Yok
    Öğe
    Management of chronic hepatitis in special hosts and special situations: A consensus report of the study group for viral hepatitis of the Turkish society of clinical microbiology and infectious diseases [Özel Konaklarda ve Özel Durumlarda Kronik Hepatit Yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu Uzlaşı Raporu]
    (AVES Ibrahim Kara, 2014) Mıstık R.; Aydın M.; Aksoy S.; Altın N.; Altunal N.; Avşar K.; Bezirgan S.; Büke Ç.; Çelik A.K.; Çelik E.; Dikici N.; Hızel K.; İskender S.; Kaya A.; Korkmaz F.; Köse Ş.; Saçlıgil C.; Sırmatel F.; Tarakçı H.; Turgut H.; Tütüncü E.; Yuluğkural Z.
    Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases convened a meeting to develop a consensus report on management of chronic hepatitis in special hosts and special situations. Relevant literature and international guidelines were reviewed, and recommendations agreed are presented at the end of each section such as therapy of chronic hepatitis B (CHB) in patients with compensated and decompensated cirrhosis, prevention and therapy of recurrent hepatitis B after liver transplantation, management of fulminant hepatitis B, therapy of CHB in hemodialysis patients, management of CHB in nonliver solid organ transplant recipients, management of CHB in immunosuppressed nontransplant patients, therapy of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection, management of HBV and hepatitis C virus (HCV) coinfection, management of CHB in alcoholic patients and injecting drug users, therapy of CHB in pregnancy and lactation period, extrahepatic manifestations in HBV infection, HBV, HCV and hepatitis D virus coinfection, therapy of chronic hepatitis C (CHC) in patients with compensated and decompensated cirrhosis, treatment of patients with recurrent HCV infection following liver transplantation, therapy of CHC in hemodialysis patients, management of CHC in nonliver solid organ transplant recipients, therapy of HCV, HBV and HIV coinfection, management of CHC in immunosuppressed nontransplant patients, HCV infection and biological agents, HCV infection and chemotherapy, management of CHC in alcoholic patients and injecting drug users, fatty liver and CHC, hemoglobinopathy and CHC, CHC in pregnancy and lactation period, extrahepatic manifestations in HCV infection. Klimik Dergisi © 2014, AVES Ibrahim Kara. All rights reserved.